Review

Crucial roles of different RNA-binding hnRNP proteins in Stem Cells

Wen Xie1,3, Hecheng Zhu1,2, Ming Zhao2, Lei Wang1,3, Shasha Li1,3, Cong Zhao1,3, Yao Zhou1,3, Bin Zhu1,3, Xingjun Jiang1,4, Weidong Liu1,3 and Caiping Ren1,3

1. Cancer Research Institute, Department of Neurosurgery, School of Basic Medical Science, Xiangya Hospital, Central South University, Changsha 410008, China.
2. Changsha Kexin Cancer Hospital, Changsha, Hunan 410205, China.
3. The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha 410008, China.
4. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.10.27; Accepted: 2021.01.07; Published: 2021.02.08

Abstract

The self-renewal, pluripotency and differentiation of stem cells are regulated by various genetic and epigenetic factors. As a kind of RNA binding protein (RBP), the heterogeneous nuclear ribonucleoproteins (hnRNPs) can act as “RNA scaffold” and recruit mRNA, lncRNA, microRNA and circRNA to affect mRNA splicing and processing, regulate gene transcription and post-transcriptional translation, change genome structure, and ultimately play crucial roles in the biological processes of cells. Recent researches have demonstrated that hnRNPs are irreplaceable for self-renewal and differentiation of stem cells. hnRNPs function in stem cells by multiple mechanisms, which include regulating mRNA stability, inducing alternative splicing of mRNA, epigenetically regulate gene expression, and maintaining telomerase activity and telomere length. The functions and the underlying mechanisms of hnRNPs in stem cells deserve further investigation.

Key words: Heterogeneous nuclear ribonucleoprotein, Stem cell, mRNA stability, Epigenetic regulation, Telomere length and telomerase activity

Introduction

Stem cells are characterized by self-renewal and the potential of multidirectional differentiation. In 1963, hematopoietic stem cells were found in the spleen, which pioneered a field for stem cell research [1, 2]. From then on, the study of stem cells has attracted more and more attention. In mammals, there are two types of stem cells, embryonic stem cells and adult stem cells. Embryonic stem cells (ESCs) are derived from blastocyst, which are developmentally pluripotent and can theoretically differentiate into almost all types of cells and organs of an organism. Adult stem cells (ASCs) exist in various tissues, which include hematopoietic stem cells, neural stem cells, mesenchymal stem cells, and retinal stem cells. ASCs also have some differentiation capacity and can be directed to differentiate into specific types of cells. According to their differentiation potential, stem cells can be divided into totipotent stem cells, pluripotent stem cells, multipotent stem cells, and unipotent stem cells. In view of the multidirectional potential of stem cells, researchers regard them as the seeds of cells, tissues and organs for replacement therapy. However, the most commonly used cell lines for stem cell research are not embryonic stem cells, but reprogrammed induced pluripotent stem cells (iPS cells). Through lentiviral transfection, transcription factors (such as Oct4, Sox2 and Nanog) are transferred into mammalian adult cells to dedifferentiate the adult cells into pluripotent stem cells, which are known as iPS cells with embryonic stem cell
characteristics. iPS cells can reduce ethical controversy in clinical practice. In recent years, stem cell researches have obtained great successes in organ transplantation [3], treatment of tumors [4], and new drug development [5]. But due to the self-renewal capacity of stem cells, they act as a double-edged sword, which can also be transformed into malignant tumor. Therefore, the biological process of stem cells is needed to be further explored, and such exploration may bring innovative ideas for treatment of relevant diseases.

RNA-binding proteins (RBPs) are a unique class of proteins in eukaryotic cells, which interact with RNA via specific RNA-binding domains (RBDs). A single RBP functions in cells by binding to multiple RNA sequences. RBP binds to target genes through recognizing the specific nucleotide sequence of the open reading frame (ORF) or untranslated region (UTR) in their transcripts, mainly through different RBDs [6], such as RRM, K homology (KH) domain, double-stranded RNA-binding base sequence (dsRBM), zinc finger (ZF) domain, etc. [7]. However, some RBPs do not bind with RNA through RBD, but rather by affinity distribution and synergistic interactions with other effectors [8]. Recent studies indicated that RBP can affect the alternative splicing, transcription, stability and intracellular localization of bound mRNAs to change their functions, and thus participate in the self-renewal and differentiation of stem cells [9].

hnRNPs are one of the most typical kinds of RNA-binding proteins [10]. hnRNP family include hnRNPs A-U and several other RNA-binding proteins in eukaryotic cells. Most of hnRNPs are mainly located in the nucleus, while a few of them present in both the nucleus and cytoplasm [11]. hnRNPs can regulate mRNA splicing [12] and stability [13], gene transcription and translation [14], DNA damage repair, and telomere length maintenance [15]. As nucleoplasmic shuttle proteins, they play significant roles in cell signaling processes. It has been found that hnRNPs not only serve as therapeutic targets and prognostic biomarkers in tumors, but also play important roles in stemness maintenance and differentiation of stem cells.

In recent years, some reviews have illustrated how hnRNPs regulate the biological function of cells [15] and their roles in the occurrence and development of relevant diseases [16]. For example, in the previous reviews, it was pointed out that hnRNPs can recruit IncRNAs to enrich them in the nucleus, regulate the alternative splicing of IncRNAs, and change genome structure, etc. [9, 13].

In this review, we mainly discuss the roles of hnRNPs and how they function in biological processes of stem cells.

The structure and function of hnRNPs

hnRNPs are nucleic acid metabolism family of histones that bind with transcripts produced by RNA polymerase II in the nucleus, and are involved in processes such as nucleic acid metabolism, cell differentiation, and apoptosis [11]. Among them, hnRNPA/B and C were first separated from the complex by biochemical methods (sucrose density gradient separation method) [16]. Subsequently, due to the RNA-binding specificity of the proteins, other hnRNP family member complexes were successfully identified in intact cells by using UV cross-linking, with about 20 species from A-U [17]. hnRNPs are typical RNA-binding and modular proteins, mainly composed of RNA binding motifs and auxiliary domains. The RNA binding motifs include RRM domains, RGG domains [18] and KH domains [19]. The auxiliary domains include Gly-rich, acidic domains and others. The following table shows the isoforms, molecular weights, and different domains of hnRNPs (Table 1). In summary, the molecular functions of hnRNPs vary depending on their specific domains, RNA recognition motifs (Figure 1), post-translational modification sites and cellular localization.

At DNA level, hnRNPs are involved in DNA replication, transcription, damage repair, chromatin remodeling, telomerase activity and telomere length maintenance. At RNA level, they play important roles in maintaining the stability of mRNA, and participate in RNA splicing. At protein level, hnRNPs can affect protein translation and degradation by binding to other proteins.

In addition to affecting other genes at DNA, RNA and protein levels, hnRNPs can alter their own nucleo-plasmic shuttling, subcellular localization, and metabolism through phosphorylation, ubiquitination, and other post-translational modifications. Post-translational modification (PTM) refers to the chemical modification of a protein after translation. For most proteins, this is a later step in protein biosynthesis. PTM includes protein ubiquitination, phosphorylation, methylation, acetylation, sumoylation and so on. For example, the MAPK/ERK signaling pathway activates hnRNPK phosphorylation at Serines 284 and 353 in hepatocellular carcinoma, leading to the entry of hnRNPK from the nucleus into the cytoplasm and an increase in its protein level in the cytoplasm [20]. E3 ubiquitin ligase ZFP91 promotes ubiquitination of oncoprotein hnRNPA1 at lysine 8 and subsequent proteasomal degradation, thereby resulting in inhibition of hnRNPA1-dependent PKM splicing and
suppression of glucose metabolism in HCC [21]. In addition, the post-translational modification of hnRNPs affects the binding of hnRNPs to certain proteins and RNAs, and regulates mRNA stability [22, 23]. hnRNPA2/B1 is regulated by lncRNA molecules. When lncRNA mir503HG and hnRNPA2/B1 form complexes in HCC, hnRNPA2/B1 protein ubiquitination is promoted, the stability of P52 and P65 mRNAs is reduced, and the NF-kappa B pathway of HCC is inhibited [24]. The following table contains the different modification sites for hnRNPs (Table 1).

RNA-binding motifs are required for every member of the hnRNP family. Except for hnRNPE, hnRNPK and hnRNPU, all other members have at least one RRM domain. In addition to RRM, KH and RGG domains are also RNA binding motifs, which play a major role in the biological functions of hnRNPs. The Gly rich domain and the acid rich domain belong to auxiliary domains. The auxiliary domains perform together with RNA binding motif to help RNA binding protein to function. Among different hnRNPs, there are both the same and different RNA binding motifs and auxiliary domains. Therefore, the members of hnRNPs share common RNA binding characteristics, but the binding sites are different.

Table 1. Structural and functional characteristics of the hnRNPs

| hnRNPs (Aliss) | Isoform | Molecular weight (kDa) | RNA-binding domain | Modification sites | Location |
|---------------|---------|------------------------|-------------------|-------------------|---------|
| hnRNPA/B      | A0, A1, A2/B1, A3 | 34-40 | 2×RRM, Gly rich, RGG | Methylation site: Arg-266; Sumoylated in exosomes | Nucleus, cytoplasm |
| hnRNPC        | C1, C2 | 41/43 | 2×RRM, acid rich | Phosphorylation site: Ser-260, Ser-299; hnRNPA C1 is modified by SUMO at lysine 237 | Nucleus |
| hnRNPD (AUF1) | E1, E2, E3, E4 | 44-48 | 2×RRM | Dimethylation site: Arg-345 | Nucleus, cytoplasm |
| hnRNPE        | 53 | 3×KH | | | Nucleus |
| hnRNPF        | 43 | 3×qRRM, 2×Gly rich | | | Nucleus |
| hnRNPG (RBMX) | H1, H2, H3 | 50-60 | 3×qRRM, 2×Gly rich | Sumoylated | Nucleus, cytoplasm |
| hnRNPH        | 59 | 4×RRM | | | Nucleus |
| hnRNPK (AUUKS)| 68 | 4×RRM, Gly rich | | | Nucleus |
| hnRNPM (CEAR) | 55-65 | 3×KH, other | | | Nucleus, cytoplasm |
| hnRNPFQ (SYNCRIP) | Q1, Q2, Q3 | 55-70 | 3×RRM, acid rich | | Nucleus |
| hnRNPR        | 71 | 3×RRM, acid rich, RGG, other | | | Nucleus |
| hnRNPU (SAF-A)| 120 | Acid rich, Gly rich, RGG, other | | | Nucleus |
| hnRNPP2 (FUS/TLS)| 72 | 2×Gly rich, RRM, 2×RGG | Dimethylation site: Arg-216, Arg-218; Phosphorylationsite: N-terminal region | Nucleus |
| hnRNPP2 (FUS/TLS)| 72 | 2×Gly rich, RRM, 2×RGG | Dimethylation site: Arg-216, Arg-218; Phosphorylationsite: N-terminal region | Nucleus |

Figure 1. The schematic of the hnRNP domains.
Table 2. Molecular functions and mechanisms of hnRNPs in stem cells

| hnRNPs (Alias) | Bound RNA | Expression | Function | Mechanism |
|----------------|-----------|------------|----------|-----------|
| hnRNPI (PTBP1) | Pnky, ANCR | High | Inhibit the differentiation of stem cells | Maintain mRNA stability [28] |
| hnRNPI (PTBP1) | UCA1 | High | Involved in the development of red blood cells | Maintain mRNA stability [36] |
| hnRNPIQ2 (SYNCRIP) | MS2 | High | Maintain the self-renewal capacity of leukemia stem cells | Maintain mRNA stability [33] |
| hnRNPA1 (ALS19) | β-HIB | High | Maintain self-renewal of blood vessel cells and delay aging | Maintain mRNA stability [43] |
| hnRNPD (AUFI) | Argonaute 2 | High | Promote myoblast differentiation | Degrade mRNA [22,43] |
| hnRNPE1 (Pcbp1) | GRHL3, KLF4 | High | Inhibit myoblast differentiation | Maintain mRNA stability [46] |
| hnRNPF/H | TCF3 | Low | Differentiation of human embryonic stem cells into the outer germ layer | Alternative splicing of mRNA [51-53] |
| hnRNPA2/B1 | D-aminolevulinic Acid Oxidase | Low | Induce the occurrence of ALS disease | Alternative splicing of mRNA [57,58] |
| hnRNPA1 (ALS19) | TRAF6 | High | Bone marrow differentiation | Alternative splicing of mRNA, exon skipping [62] |
| hnRNPLL | PABPC1 | High | Promote the differentiation of B cells into plasma cells | Alternative splicing of mRNA [66] |
| hnRNPA2/B1 | | | | |
| hnRNPU (SAF-A) | | | | |
| hnRNPK | | | | |
| hnRNPF/H | | | | |

The functions and the underlying mechanisms of hnRNPs in stem cells

hnRNPs function in stem cells through multiple mechanisms (Table 2). The mechanisms of hnRNPs mainly include: (1) hnRNPs bind directly with mRNAs or form complexes with lncRNAs and mRNA to regulate mRNA stability. (2) hnRNPs bind with mRNA and induce alternative splicing. (3) hnRNPs affect embryonic development by epigenetic modification. (4) hnRNPs regulate telomerase activity and telomere length in stem cells.

hnRNPs regulate mRNA stability and gene transcription in stem cells

As typical RNA-binding proteins, hnRNPs play a vital role in mRNA stability and gene transcription regulation. hnRNPs bind with lncRNA in stem cells to form complexes with mRNA or directly bind with mRNA, thus affecting the stability of mRNA. Pnky is a lncRNA presented in embryonic brain with neural-specific functions and regulates neural stem cells (NSCs) in life activities. Knockdown of Pnky leads to the differentiation of NSC in mouse embryonic brain. Poly(C)tract binding protein 1 (PTBP1 or hnRNPI) is an effective regulator of the neurogenesis, which has been shown in previous studies [25]. Knocking down PTBP1 leads to premature differentiation of NSC in mouse brain and impairs motor behavior [26], while PTBP1 can affect neuronal gene expression by regulating the transcription factor Pbx1 [27]. Through RNA pull down experiment and RNA immunoprecipitation technique, Pnky and PTBP1 were found to specifically bind to each other. After Pnky and PTBP1 were knocked down respectively, it was found through DEX-Seq [28] sequencing that there were a common part of transcription alterations that affect the differentiation of NSCs and regulate neurogenesis and neuronal development [26]. A new study has shown that PTBP1 can bind and stabilize ID2 mRNA by interacting with lncRNA ANCR, thus inhibiting the differentiation of human adipogenic mesenchymal stem cells (hAMSCs) into defined endoderm cells and reducing the occurrence of liver and pancreatic diseases [29].

Most members of the hnRNPs have similar roles because they share the same structural domains and components. It is anticipated that the members may participate in cellular biological processes by binding to each other and forming complexes together. For example, when studying the self-renewal and glycolytic pathways of mouse embryonic stem cells, lncRNA Lncenc1 was found to have the highest expression [30], and through biotin labeling, Lncenc1 was then found to bind to hnRNPK and PTBP1. Previously, it has been proved through yeast two-hybrid technology that hnRNPK and PTBP1 bind to each other [31]. Using chromatin immunoprecipitation (ChIP) and chromatin isolation by RNA purification analysis, hnRNPK was found to bind with the promoter of glycolysis gene and directly regulate the transcription of glycolysis gene. When hnRNPK and PTBP1 are knocked down respectively, the glycolysis gene will be down-regulated and lactate production will be reduced. The above results indicate that Lncenc1, hnRNPK and PTBP1 form complexes to promote glycolytic pathway and maintain the self-renewal of mouse embryonic stem cells. PTBP1 is involved in the transcriptional regulation in cells and controls the stability of mRNA. In the development of erythropoiesis, heme, an important component of hemoglobin, is a part of the stabilizing regulators [32, 33]. Heme first activates a series of enzymatic reactions through the red cell specific gene 5-aminolevulinic acid synthase 2.
(ALAS2, or ALASE) [34, 35], and then it is synthesized in the proerythroblast. In contrast, once ALAS2 gene expression is too low, it will lead to insufficient heme synthesis, resulting in the differentiation of proerythroblast and anemia [36]. In the study of erythroid differentiation, it was found that IncRNA UCA1 can act as a RNA scaffold, and specifically bind hnRNPI to recruit ALAS2 mRNA and control its stability. Keeping the transcription and translation of the ALAS2 gene under control for a relatively stable state, quantitative heme can be synthesized to participate in the development of red blood cells [37].

Acute myeloid leukemia (AML) is a malignant transformation of myeloid hematopoietic stem/progenitor cells that can be life-threatening if not detected and treated early [38, 39]. At present, it has been found that hnRNPs can regulate mRNA stability of the key factors in leukemia stem cells, thereby affecting the occurrence and development of leukemia. It provides a new therapeutic target for the treatment of leukemia. For example, MS12 is a critical factor participating in self-renewal of leukemia stem cells (LSCs) [35]. With the proteomics analysis of RBP networks in LSC involving MS12 protein interaction and functional shRNA screening, highly expressed SYNCRIP (or hnRNPF1) was identified. SYNCRIP indirectly binds to MS12 and interacts with a common mRNA target, HOXA9, thus maintaining its transcription and translation, inhibiting apoptosis and promoting leukemia [34]. Recently, hnRNPD overexpression was found to be involved in the induction of chronic myelogenous leukemia (CML). hnRNPD recognizes the special substrate sequence AUUAGC in PBX1 3'-UTR and binds with it, thus stabilizing PBX1 mRNA, promoting its translation, and allowing the colony-forming cells (CFCs) to produce more CML CD34+ cells, which provides a new treatment strategy for chronic myeloid leukemia [36]. Knocking down hnRNPD in CML cells results in down-regulation of PBX1 expression, which inhibits CML cell growth and lead to sensitization of CML cells to imatinib.

Calorie intake has been previously reported to play a role in cellular aging [40, 41]. Ketone body β-hydroxybutyrate (β-HB) acts as an intermediate metabolite in fat oxidative metabolism to prevent aging. The direct binding of β-HB to hnRNPA1 was found by using MALDI-TOF mass analysis [42]. Oct4, as a stem factor, has an anti-aging effect through its own expression. Knocking down Oct4 causes aging partly because of induced DNA damage. In endovascular cells, the mRNA stability test showed that hnRNPA1, in the presence of β-HB, can enhance the stability of Oct4 mRNA and enable the normal expression of Oct4 and its downstream LaminB1, which is one of the key factors to resist senescence induced by DNA damage [43]. Therefore, β-HB can maintain the self-renewal of endovascular cells and delay senescence by up-regulating hnRNPA1 and inducing Oct4-mediated LaminB1 pathway [44].

There are two main causes for the occurrence of diseases such as muscle weakness and muscle atrophy. One is the bone damage caused by strenuous exercise or serious accident, which leads to the damage of skeletal muscle stem cells and myoblast cells and the impairment of muscle regeneration. The other is that as muscle stem cells grow older, their ability to self-renew and reproduce decreases. Chenette et al. argued that AUF1 (or hnRNPD) can act as a regulator in adult muscle stem cells, which is important in skeletal muscle formation [45]. Meanwhile, Abbadi et al. found that AUF1 can target and regulate Twist1 mRNA by combining the AU-rich elements (AREs) in the 3'-UTR, which rapidly degrades Twist1 mRNA and leads to the weakening of self-renewal of muscle stem cells and the differentiation of myogenic cells [46]. It follows that hnRNPs can play a significant role in skeletal muscle growth and muscle injury repair by regulating the stability of mRNA.

In addition to IncRNA, microRNA, as a kind of non-coding small RNA, can also directly regulate gene post-transcriptional expression or stabilize its own expression by binding to RBPs and functioning together in cells. High expression of PCBP1 (also known as hnRNPE1 or CP-1) was found in mouse myoblasts, and the hybrid offspring of PCBP1 mutant mice showed fetal death, indicating that PCBP1 plays a crucial role in the growth and development of mice. In 2017, Espinoza et al. found that PCBP1 combines with Argonaute 2 to stabilize miR-1, miR-133, and miR-206 in muscle cells, which contributes to the expression and processing of these miRNAs in myoblasts, inhibits the conversion of fast to slow muscle fibers in muscles, and regulates the contraction and relaxation of skeletal muscles [47].

hnRNPs not only can recruit IncRNA and microRNA to regulate the expression of downstream target genes and affect the stability of their mRNA to participate in the development process of stem cells, but also can maintain the pluripotency of stem cells and prevent premature differentiation by directly binding and degrading mRNA with the function of promoting cell differentiation. Recent results have shown that hnRNPK can prevent premature differentiation of epidermal progenitor cells by directly binding and degrading GRHL3 and KLF4 transcripts, while knocking down hnRNPK leads to cell differentiation [48].
hnRNPs regulate the alternative splicing of mRNA in stem cells

Alternative splicing (AS) can affect the transcriptional regulation and translation of genes, resulting in different or antagonistic functions of the final protein and different meanings in cell activities [49, 50]. mRNA splicing can be used as a gateway to control stem cell pluripotency and differentiation. The generation of AS can be broadly divided into three categories, i.e., exon jump, mutually exclusive exons, and intron retention [51]. hnRNPs, a well-known family of splicing proteins, have been widely studied, and great relevant advances in the field of stem cells have been achieved in recent years. For example, hnRNPF/H can modulate the pluripotency of human embryonic stem cells by alternative splicing TCF3. TCF3 (or E2A) is a member of the transcription factor E protein family, all of which are regulated by stem factors Oct4, Nanog and Sox2, and can bind to the promoter of downstream genes that regulate the differentiation of embryonic stem cells. TCF3 possesses two isoforms generated by alternative splicing, E12 and E47, both of which are transcription factors of CDH1. CDH1 can keep mouse ESCs (mESCs) in their naive state, and interfering with CDH1 results in differentiation of mESCs into ectoderm cells [52, 53]. hnRNPF/H predominantly promotes E12 expression in human embryonic stem cells, thus elevating CDH1 protein expression and maintaining pluripotency of human embryonic stem cells. Knockdown of hnRNPF/H causes TCF3 to be spliced into E47 variant with exon 18a skipped and leads to the differentiation of human embryonic stem cells into ectoderm by inhibiting CDH1 expression [54, 55]. hnRNPF/H mainly regulates TCF3 alternative splicing by combining with the exon splicing silencer (ESS) in exon 18b of TCF3. Yamazaki et al. found another way by which the alternative splicing of TCF3 is regulated. hnRNPH1 and PTBP1 first combine with each other and then bind together to the conservative intron-spliced silencer (ISS) of TCF3, remotely regulating the variable splicing of TCF3 [56].

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressively increasing and fatal neurodegenerative disease [57]. The cause of 90-95% of the disease cases is unknown, and about 5-10% of them are inherited from parents. Most importantly, ALS has no effective cure to date. Martinez FJ et al. found that an RNA network in association with neurodegeneration, which involves alternative splicing regulated by hnRNPA2/B1. Knocking down hnRNPA2/B1 can cause changed mRNA splicing of ALS-related D-amino acid oxidase (DAO) gene, lead to the skipping of exons in DAO, and change the expression of its downstream target genes. DAO encodes an enzyme involved in D-serine metabolism, which has been reported to play a role in the excitation process of ALS [58]. Therefore, knocking down hnRNPA2/B1 will eventually lead to decrease in D-serine metabolism, resulting in ALS disease [59].

Toll-like receptors (TLRs) have a function in human body to regulate myelogenesis, but prolonged activation of TLR causes dysfunction in the production of hematopoietic stem/progenitor cells (HSPCs), leading to malignant blood disorders [60]. TNF receptor-associated factor-6 (TRAF6) is an E3 ligase, and acts as a TLR effector with ubiquitin (Ub) ligase activity. Once overexpressed in HSPC, it activates TLR to promote the development of myelodysplastic syndrome [61, 62]. By using human leukemia cell lines overexpressing TRAF6, Fang et al. performed a global semi-quantitative Ub screening and a TRAF6 substrate ubiquitin screening, and revealed that as one of the substrates, hnRNPA1 is ubiquitinated by TRAF6. Exon expression microarray analysis showed a high enrichment of exons associated with RNA-binding proteins, and subsequent in-depth studies revealed that TRAF6 leads to jumping of exon 2 of Arhgap1 primarily through ubiquitination of hnRNPA1, resulting in truncated ORF-encoded Arhgap1 protein and increased cdc42 activity, and the ultimate manifestation is myelogenous differentiation and severely hampered hematopoiesis [63].

The maintenance of the body’s immune system against viruses is largely dependent on immunoglobulins secreted by plasma cells. Plasma cells are differentiated from B cells and are at the terminal stage of B lymphocytes. By comparing the proteomics of B cells and plasma cells, it has been found that one of the RNA-binding proteins exhibits significant difference. hnRNPLL expression level is lower in B cells, while it increases significantly in plasma cells. In order to investigate the role of hnRNPLL in the differentiation of B cells into plasma cells, Chang X et al. used Photoactivatable-Ribonucleoside-Enhanced Cross-Linking and Immunoprecipitation (PAR-CLIP) [64, 65] and RNA sequencing methods to search for hnRNPLL target genes, and found that hnRNPLL mainly binds with 3'UTR of target mRNAs. It is well known that the 3'-UTR is one of the cis-acting elements that regulates mRNA stability and translation. The expression of target genes is significantly decreased after knocking down hnRNPLL. It follows that the binding of hnRNPLL with 3'-UTR enhances the stability of mRNAs in cells [66]. In plasma cells, hnRNPLL
regulates the transition from membrane isoform to secreted isoform of immunoglobulin heavy chain through binding to RRM1 domain of PABPC1 in plasma cells, but the exact mechanism remains to be investigated [67].

hnRNPs epigenetically regulate gene expression to affect embryonic development

The modification of N6-methyladenosine (m6A) is one of the most common modifications involved in mRNA regulation in eukaryotic cells. What’s more, it is a current hot-spot research area. The current results indicate that m6A modification plays a crucial role in regulating the life activity of stem cells, which maintains their pluripotency and promotes stem cell transformation [68-70]. m6A modification can enhance the interaction of RNAs and RNA-binding proteins and thus function at post-transcriptional level.

As one of the “readers” of m6A, hnRNPs can recognize the methylation sequence on RNAs. The “m6A-switch” mechanism says that m6A regulates the interaction between RNAs and proteins by reconstructing part of RNA structure. For example, hnRNPC binds to m6A-modified RNA through an “m6A-switch” mechanism. When the m6A-mediated “RNA hairpin” is lost, the single-stranded hnRNPC-binding motif is exposed and its function is altered [71]. Alternative splicing of mRNA and target gene expression occur upon binding of the low-complexity region at the C-terminal end of the hnRNPG molecule with m6A [72]. However, the role of hnRNPA2/B1 in m6A regulator is controversial among different research groups. Since the initial discovery in 2015, hnRNPA2/B1 has been recognized as the m6A “writer”, which can interact with numerous nuclear transcripts and regulate their alternative splicing [73]. In 2018, Wu et al. confirmed by bioinformatics combined with experiments that hnRNPA2/B1 can regulate m6A modifications through an “m6A-switch” mechanism, rather than affect them directly [74]. In 2019, it was further shown that knocking down hnRNPA2/B1 delays mouse embryonic development. Meanwhile, knock-down of MELLT3, a methyltransferase that catalyzes m6A methylation, can induce developmental defects that prevent the formation of embryos. To further confirm the link among hnRNPA2/B1, m6A, and MELLT3, Immunocytochemistry (ICC) was used to detect the localization of m6A. Knocking down of MELLT3 resulted in reduced hnRNPA2/B1 and m6A levels. It was also found that hnRNPA2/B1 is regulated by METTL3-dependent m6A RNA methylation to maintain the self-renewal in mouse embryonic development [75].

Chromosome inactivation, also known as lyonization, is an epigenetic event at which one of the two X chromosomes in cells of female mammals is concentrated and heterochromatinized due to the inactivation of this X chromosome called inactive X chromosome (Xi) [76]. One gene that plays a crucial role in the formation of Xi is X inactive-specific transcript (Xist), whose expression product acts as a long non-coding RNA and participates in epigenetic modification. It induces the formation of heterochromatin by recruiting transcriptional silencing complexes.

hnRNPU (or SAF-A), as one of the proteins forming the nuclear matrix, was found by Hasegawa et al. to interact with Xist RNA via its RGG RNA binding domain, which was confirmed by UV cross-linking analysis. In cultured mouse neuroblastoma cell line Neuro2a and mouse embryonic fibroblasts (MEFs), researchers found by immunofluorescence that after hnRNPU is knocked down, Xist is detached from the Xi, moves toward the nucleoplasm and disperses. hnRNPU-deficient mice exhibit early embryonic lethality after hybridization [77]. However, Kolpa et al. expressed inconsistent views. They knocked hnRNPU down in multiple cell lines to verify whether it plays an important role in the enrichment of Xist RNA on Xi chromosome and has generalizability. The results showed consistency with Hasegawa et al. only in the mouse Neuro2a cell line. But in MEF cells and renal cells, Xist RNA was not fully released [78]. Basic research permits disputes and queries. Sakaguchi, one researcher of Hasegawa’s experimental team, explained that the discrepancy could be due to inefficient hnRNPU knockdown resulted from different vectors, transfection agents, and experimental methods used in other labs. He added more experimental data to prove his team’s point [79].

Xist RNA is able to recruit transcriptional silencing complexes to play a role mainly because it possesses a Xist RNA Polycomb-Interaction-Domain (XR-PID), and once the XR-PID is deleted, Xist RNA is unable to recruit those transcriptional silencing complexes and further induce the formation of Xi. Some studies have indicated that knocking down Polycomb group RING finger 3/5 (PCGF3/5-PRC1) can lead to the death of female embryos [80]. Researchers have demonstrated that hnRNPK can perform functions similar to XR-PID. Pintacuda et al. found that hnRNPK can bind to XR-PID and recruit transcriptional silencing complex at the same time. Even in the absence of XR-PID, hnRNPK can still help Xist RNA recruit enough transcriptional silencing complexes, though not as efficiently as in the presence of XR-PID.
of XR-PID [80]. This finding provides a new perspective on the role of interactions between non-coding RNA and RNA-binding proteins in chromatin modification.

**hnRNPs regulate telomerase activity and telomere length of stem cells**

Telomeres are located at the end of eukaryotic chromosomes and play a major role in protecting chromosomes, preventing chromosome degradation and stabilizing genomes. The length of telomeres is regulated by telomerase, a special DNA polymerase. In general, the presence of active telomerase can only be detected in embryonic stem cells and pluripotent stem cells, which can prolong the damaged telomere and increase the number of cell division, and is also the fundamental cause for the continuous division ability of embryonic stem cells and pluripotent stem cells [81-83].

It is well known that hnRNPs belong to a typical RNA-binding protein family, but due to their RRM domains, hnRNPs can not only bind RNA, but also have the ability to bind DNA. Some hnRNPs can bind telomere DNA to regulate telomerase activity, and some can directly bind telomerase to affect cell function [15, 84].

hnRNPF/H is mostly expressed in undifferentiated stem cells, including embryonic stem cells, which are in a naïve state, and in adult stem cells such as human mesenchymal stem cells (hMSC). hnRNPF/H has been mainly studied as a shear factor, which can regulate the stability of mRNA, and is involved in gene transcriptional process of cells. A recent study indicated that after knocking down hnRNPF/H, the proliferation of mesenchymal stem cells is slowed down and even cell senescence occurs. It has been shown that the growth of MSCs is closely related to the length of telomeres and the activity of telomerase [85, 86]. With further differentiation of MSCs into chondrocytes, the length of telomeres gets shorter and the activity of telomerase decreases. To explore whether hnRNPF/H knockdown induced aging of MSCs is related to telomeres and telomerase activity, Xu et al. performed biotin RNA pull-down and RNA-IP experimental studies, and revealed that hnRNPF/H binds to the 5'-end of human telomerase RNA component (hTERC), one of the components of telomerase, and the first three G regions of hTERC bind with the RRM1 domain of hnRNPF/H [87]. hTERC and human telomerase reverse transcriptase (hTERT) are important components of telomere formation complex. Using the hTERC as a template, the telomerase DNA is added to the ends of chromosomes to maintain telomere length, which is catalyzed by hTERT [88]. After overexpression of hnRNPF/H, the proliferative capacity of mesenchymal stem cells is enhanced. The revealed new role of hnRNPF/H in the regulation of telomeres and telomerase in stem cells brings new directions and ideas for future stem cell research [87].

**Conclusions and perspectives**

In this review, we have described the mechanisms by which the RNA-binding protein hnRNPs maintain the self-renewal capacity of stem cells and participate in the stem cell differentiation process. The main mechanisms include the followings: 1. hnRNPs regulate the stability of mRNA in stem cells. 2. hnRNPs regulate alternative splicing of mRNAs in stem cells. 3. hnRNPs epigenetically regulate gene expression and affect embryonic development. Firstly, hnRNPs are involved in regulation of m6A modification to affect the transcription of surrounding mRNAs and thus maintain stem cell self-renewal. Secondly, hnRNPs bind with Xist RNA and are involved in chromatin modification. 4. hnRNPs regulate telomerase activity and telomere length in stem cells (Figure 2).

Although some progresses have been made in the research field of hnRNPs, the functions played by hnRNPs in stem cells deserve further investigation. To date, many achievements and breakthroughs have been obtained about the roles of hnRNPs in the occurrence and development of malignant tumors. For example, hnRNPs play a role in inhibiting epithelial-mesenchymal transition (EMT) [89], and in cell invasion and apoptosis through TGF-β [90, 91], AKT [92], p53 [93, 94], and other signaling pathways, suggesting that hnRNPs may be used as novel therapeutic targets. In addition to family heredity, somatic gene mutations, influence of external environment and uncontrolled self-renewal capacity of the body’s stem cells contribute a lot to the occurrence of malignant tumors and other diseases. Therefore, the study of the activities of stem cells in the organism is of great scientific significance. However, there are relatively less studies on the mechanism of hnRNPs in stem cells compared to cancers at present. Meanwhile, in the existing stem cell studies, the majority of the individual hnrNP family members have been investigated through their interactions with RNAs and other proteins. Rare exploration is focused on the interactions among hnRNPF members in biological processes of stem cells, which is likely to reveal new biological functions of hnRNPs. It is interesting that some hnRNPs can function by binding to the same RNA molecule. The combination of L2 mRNA with hnRNPF E1, E2, and K inhibits the translation of human papillomavirus type 16 [95]. The interactions among hnRNPs members
have been detected by the yeast two-hybrid system and in vitro co-precipitation assays. The results showed that hnRNPE2 and hnRNPK can bind with each other through their KH domains, and the RRM2 domains in hnRNPI and hnRNPL play a crucial role in their protein-protein binding [30]. In addition to binding to each other through their specific domains, the interaction among hnRNPs is also promoted by their PTMs, such as phosphorylation. For example, when studying the mechanism of tumors, it was found that vascular endothelial growth factor (VEGF)-A generated by cells in the process of hypoxia and inflammation is an important cause of angiogenesis. Yao et al. found that hypoxia can induce hnRNPL phosphorylation at Tyr359, which promotes its combination with hnRNPA2B1, and at the same time, phosphor-hnRNPL recruits DRBP76 (double-stranded RNA binding protein 76) to bind to 3'UTR of VEGFA. This unique HILDA (hypoxia-inducible hnRNPL-DRBP76-hnRNPA2/B1) complex allows VEGFA to be stably translated during hypoxia and inflammatory processes [96]. This discovery suggests that hnRNPs can bind to each other through phosphorylation or other post-translational modifications and work together in cells. These results bring a new perspective for future research on how different hnRNP members work together to regulate the biological processes of stem cells.

**Abbreviations**

hnRNPs: the heterogeneous nuclear ribonucleoproteins; ESCs: embryonic stem cells; ASCs: adult stem cells; RBPs: RNA-binding proteins; RBD: RNA-binding domains; ORF: open reading frame; UTR: untranslated region; KH: K homology; dsRBM: double-stranded RNA-binding base sequence; ZF: zinc finger; RRM: RNA recognition motif; PTM: post-translational modification; NSCs: neural stem cells; PTBP1: polypyrimidine tract binding protein 1; hAMSCs: human adipogenic mesenchymal stem cells; ChIP: chromatin immunoprecipitation; ALAS2: aminolevulinic acid synthase 2; AML: acute myeloid leukemia; LSCs: leukemia stem cells; CML: chronic myelogenous leukemia; CFCs: colony-forming cells; β-HB: β-hydroxybutyrate; AREs: AU-rich elements; AS: alternative splicing; mESCs: mouse ESCs; ESs: exon splicing silencer; ISS: intron-spliced silencer; ALS: amyotrophic lateral sclerosis; DAO: D-amino acid oxidase; TLRs: Toll-like receptors; HSPCs: hematopoietic stem/progenitor cells; TRAF6: TNF receptor-associated factor-6; Ub: ubiquitin; PAR-CLIP: Photoactivatable-Ribonucleoside-Enhanced
Cross-Linking and Immunoprecipitation; m6A: N6-methyladenosine; Xist: X inactive-specific transcript; MEFs: mouse embryonic fibroblasts; XR-PID: Xist RNA Polycomb-Interaction-Domain; PCGF3/5-PRC1: Polycomb group RING finger 3/5; hHMSC: human mesenchymal stem cells; hTERC: human telomerase RNA component; hTERT: human telomerase reverse transcriptase; VEGFA: vascular endothelial growth factor (VEGF)-A.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (82071399,81773179,30871246,81070993 and 81472355), Provincial Natural Science Foundation of Hunan (2020JJ4771,2016J2172), National Key Research and Development Program of China (2016YFC1101502), Hunan Provincial Science and Technology Department (2014FJ6006), Independent Exploration and Innovation Project of Central South University (2020zzts773).

Author Contributions

RCP, LWD and JXJ contributed to design the study. XW prepared and wrote the manuscript. ZHC, ZM and LWD have modified the table. RCP, LWD, JXJ, ZB, LSS, ZC and ZY critically reviewed and revised the manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963; 197:452-4.
2. Siminovitch L, McCulloch EA, Till JE. The distribution of colony-forming cells among spleen colonies. Journal of Cellular and Comparative Physiology. 1963; 62:325-36.
3. Mansour AA, Goncalves JT, Bloyd CW, et al. An in vivo model of functional and vascularized human brain organoids. Nature Biotechnology. 2018; 36:772.
4. Ge Y, Fuchs E. Stretching the limits: from homeostasis to stem cell plasticity in wound healing and cancer. Nature Reviews. 2018; 19:311-25.
5. Little D, Ketteler R, Gissen P, et al. Using stem cell-derived neurons in drug screening for neurological diseases. Neurobiology of Aging. 2019; 78: 130-41.
6. Hattori A, Buco K, To T. Regulation of stem cell self-renewal and oncogenesis by RNA-binding proteins. RNA Processing. 2016; p: 153-88.
7. Schlundt A, Tants J-N, Sattler M. Integrated structural biology to unravel molecular mechanisms of protein-RNA recognition. Methods. 2017; 118:119-36.
8. Jankowsky E, Harris ME. Specificity and nonspecificity in RNA-protein interactions. Nature Reviews Molecular Cell Biology. 2015; 16:533-44.
9. Xu Y, Wu W, Han Q, et al. Post-translational modification control of RNA-binding protein hNRNP K function. Open Biology. 2019; 9.
10. Wang H, Liang L, Dong J, et al. Long non-coding RNA m60301HG, a prognostic indicator, inhibits tumor metastasis by regulating the hNRNPAB1/NF-kappa B pathway in hepatocellular carcinoma. Theranostics. 2018; 8: 2814-29.
11. Keppetipola N, Sharma S, Li Q, et al. Neuronal regulation of pre-mRNA splicing by polyypyrimidine tract binding proteins, PTBP1 and PTBP2. Critical Reviews in Biochemistry and Molecular Biology. 2012; 47: 360-78.
12. Shibasaki T, Tokunaga A, Sakamoto R, et al. PTB deficiency causes the loss of adherens junctions in the dorsal telencephalon and leads to lethal hydrocephalus. Cerebral Cortex. 2013; 23: 1824-35.
13. Linares AJ, Lin C-H, Diamanov A, et al. The splicing regulator PTBP1 controls the activity of the transcription factor Pbx1 during neuronal differentiation. Elife. 2015; 4.
14. Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNA-seq data. Genome Research. 2012; 22: 2008-17.
15. Li J, Yang Y, Fan J, et al. Long non-coding RNA ANCR inhibits the differentiation of mesenchymal stem cells toward definitive endoderm by facilitating the association of PTBP1 with ID2. Cell Death & Disease. 2019; 10.
16. Sun Z, Zhu M, Lv P, et al. The long non-coding RNA Lnenc1 maintains naive states of mouse iSCs by promoting the Glycolysis pathway. Stem Cell Reports. 2018; 11: 741-55.
17. Kim JH, Baham B, Kim YK, et al. Protein-protein interaction among hNRNP s shuttling between nucleus and cytoplasm. Journal of Molecular Biology. 2000; 298: 395-405.
18. Maynadie M, Giroudon F, Manivet-Janoray I, et al. Twenty-five years of cross linking and immunoprecipitation; hNRNP K and inhibition of mRNA translation. Nature cell biology. 2001; 3: 8558-72.
19. Anton SD, Karabetian C, Heekin K, et al. Caloric restriction to moderate renal senescence of aged rats by increasing autophagic activity and reducing oxidative damage. Mechanisms of Ageing and Development. 2013; 134: 570-9.
20. Antón SD, Karabetian C, Heekin K, et al. Caloric restriction to moderate senescence: mechanisms and clinical utility. Current translational geriatrics and experimental gerontology reports. 2013; 2: 259-46.
21. Porsouliki A, Chochlikis D. Use of MALDI-TOF mass spectrometry in the battle against bacterial infectious diseases; recent achievements and future perspectives. Expert Review of Proteomics. 2018; 15: 537-9.

http://www.ijbs.com
43. Shimi T, Butin-Israe1i V, Adam SA, et al. The role of nuclear lamin B1 in cell proliferation and senescence. Genes & Development. 2011; 25: 2579-93.
44. Han Y-M, Bedarida T, Ding Y, et al. beta-Hydroxybutyrate prevents vascular senescence through hnRNP A1-mediated upregulation of Okt4. Molecular Cell. 2018; 71: 1064-4.
45. Chenette DM, Cadwallader AR, Antwine TL, et al. Targeted mRNA decay by RNA binding protein AUFI regulates adult muscle stem cell fate, promoting skeletal muscle integrity. Cell Reports. 2016; 16: 1379-90.
46. Abbadi D, Yang M, Chenette DM, et al. Muscle development and regeneration controlled by AUFI-mediated stage-specific degradation of fate-determining checkpoint mRNAs. Proceedings of the National Academy of Sciences of the United States of America. 2019; 116: 11285-90.
47. Espinoza-Lewis RA, Yang Q, Liu J, et al. Poly (C)-binding protein 1 (Pcpbp1) regulates skeletal muscle differentiation by modulating microRNA processing in myoBlasts. Journal of Biological Chemistry. 2017; 292: 9540-50.
48. Li J, Chen Y, Xu X, et al. hnRNPF maintains epidermal progenitor function through transcription of proliferation genes and degrading differentiation promoting mRNAs. Nature Communications. 2019; 10.
49. Ule J, Blencowe BJ. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Molecular Cell. 2019; 76: 329-45.
50. Banale FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nature Reviews Molecular Cell Biology. 2017; 18: 437-51.
51. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nature Reviews Molecular Cell Biology. 2009; 10: 44-54.
52. Pieters T, van Roy F. Role of cell-cell adhesion complexes in embryonic stem cell biology. Journal of Cell Science. 2014; 127: 2603-15.
53. Redner T, Diecke S, Grigoryan T, et al. E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. Embo Reports. 2011; 12: 720-6.
54. Yamazaki T, Liu L, Lazarev D, et al. TCF3 alternative splicing controlled by hnRNPF/H regulates E-cadherin expression and HESC pluripotency. Genes & Development. 2018; 32: 1161-74.
55. Tiwari I, Yoon M-H, Park B-J, et al. Hepatitis C virus core protein induces epithelial-mesenchymal transition in human hepatocytes by upregulating E12/E47 levels. Cancer Letters. 2015; 362: 131-8.
56. Yamazaki T, Liu L, Manley JL. TCF3 mutually exclusive alternative splicing is controlled by long-range cooperative actions between hnRNPH and PTBP1. RNA. 2019; 25: 1497-508.
57. Ghasemi M, Brown RH, Jr. Genetics of amyotrophic lateral sclerosis. Cold Spring Harbor Perspectives in Medicine. 2010; 1: a002486.
58. Burnet PW J, Eastwood SL, Bristow GC, et al. D-amino acid oxidase activity is upregulated during TLR ligand stimulation might act as a trigger for the development of acute myeloid myeloid-derived suppressor cells. Journal of Clinical Investigation. 2013; 123: 4595-611.
59. Martinez FJ, Pratt GA, Van Nostrand EL, et al. Protein-RNA networks transcriptome-wide identification of binding sites of RNA-binding proteins. Nature. 2015; 518: 560-4.
60. Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand switches regulate RNA-protein interactions. Nature. 2015; 526: 459-66.
61. Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune response activity and telomere on stem progeny senescence. Biomedicine & Pharmacotherapy. 2010; 102: 9-17.
62. Patrick M, Weng N-p. Expression and regulation of telomerase in human T cell differentiation, activation, aging and diseases. Cellular Immunology. 2019; 345.
63. Wang L, Xiao H, Zhang X, et al. The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. Journal of Hematology & Oncology. 2014; 7.
64. Ford LP, Wright WE, Shay JW. A model for heterogeneous nuclear ribonucleoproteins in telomeres and telomerase regulation. Oncogene. 2002; 21: 580-3.
65. Cakouros D, Gronthos S. The changing epigenetic landscape of Mesenchymal Stem/Stromal Cells during aging. Bone. 2020; 137: 115440.
66. Serakinci N, Graaakjaer J, Kolvraa S. Telomere stability and telomerase in mesenchymal stem cells. Biochimie. 2008; 90: 33-40.
67. Martinez P, Blasco MA. Replicating through telomeres: a means to an end. Trends in Biochemical Sciences. 2015; 40: 504-15.
68. Xu C, Xie N, Su Y, et al. hnRNPF/H associate with hTERC and telomerase holoenzyme to modulate telomerase function and promote cell proliferation. Cell Death and Differentiation. 2020; 27: 1998-2013.
69. Grelot S, Link LA, Howley B, et al. A regulated PNUTS mRNA to IncRNA splice switch mediates EMT and tumour progression. Nature cell biology. 2017; 19: 1105-9.
70. Sun X-L, Wang Z-L, Wu Q, et al. LncRNA RMST activates TAK1-mediated NF-kappa B signaling and promotes activation of microglial cells via competitively binding with hnRNPK. Iubmb Life. 2019; 71: 1785-93.
71. Wosley AN, Dalton AC, Hussey GS, et al. TGF beta promotes breast cancer stem cell self-renewal through an IL6/ILFIR signaling axis. Oncogene. 2019; 38: 3794-811.
72. Kleemann M, Schneider H, Unger K, et al. MIR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells. Scientific Reports. 2018; 8.
73. Oda T, Yamazumi Y, Hiroko T, et al. Me-x-3B induces apoptosis by inhibiting m6A in mammalian neurons. Journal of Biological Chemistry. 2020; 295: 1-10.
74. Alonzo CR, Goodarzi H, Lee H, et al. hnRNPA2B1 is a mediator of m6A-dependent nuclear RNA processing events. Cell. 2015; 162: 1299-308.
75. Liu N, Zhou K, Parkin M, et al. N-6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Research. 2017; 45: 6851-63.
76. Liu Y, Bedarida T, Ding Y, et al. mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. Science. 2015; 347: 1002-6.
77. Liu N, Dai Q, Zheng G, et al. N-6-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015; 518: 560-4.